Table of Content

1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.3 STUDY SCOPE 21
1.3.1 MARKETS COVERED & REGIONAL SCOPE 21
1.3.2 INCLUSIONS & EXCLUSIONS 22
1.3.3 YEARS CONSIDERED 22
1.4 CURRENCY CONSIDERED 23
1.5 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 26
2.1.2.1 Primary sources 26
2.1.2.2 Key data from primary sources 27
2.1.2.3 Key industry insights 28
2.1.2.4 Breakdown of primary interviews 28
2.2 MARKET SIZE ESTIMATION 29
2.2.1 BOTTOM-UP APPROACH 29
2.2.1.1 Approach 1: Company revenue estimation approach 30
2.2.2 TOP-DOWN APPROACH 35
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 36
2.4 MARKET SHARE ANALYSIS 37
2.5 STUDY ASSUMPTIONS 37
2.6 GROWTH RATE ASSUMPTIONS 37
2.7 RESEARCH LIMITATIONS 38
2.7.1 METHODOLOGY-RELATED LIMITATIONS 38
2.7.2 SCOPE-RELATED LIMITATIONS 38
2.8 RISK ASSESSMENT 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 43
4.1 FUSION BIOPSY MARKET OVERVIEW 43
4.2 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION AND COUNTRY (2023) 44
4.3 FUSION BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 44
?
4.4 FUSION BIOPSY MARKET: REGIONAL MIX (2024–2029) 45
4.5 FUSION BIOPSY MARKET: DEVELOPED VS. DEVELOPING MARKETS 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
5.2.1 DRIVERS 47
5.2.1.1 Increasing prevalence of prostate cancer and growing
geriatric population 47
5.2.1.2 Availability of reimbursements and investments by public
and private sectors 48
5.2.1.3 Rising prevalence of minimally invasive surgery 48
5.2.2 RESTRAINTS 49
5.2.2.1 High costs of fusion biopsy systems 49
5.2.2.2 Alternative methods for fusion biopsy 49
5.2.3 OPPORTUNITIES 50
5.2.3.1 Rise in prevalence of prostate cancer in emerging economies 50
5.2.3.2 Technological advancements in fusion biopsy devices 50
5.2.4 CHALLENGES 51
5.2.4.1 Paucity of skilled professionals 51
5.2.4.2 Limited reimbursement in few countries 52
5.3 PRICING ANALYSIS 52
5.3.1 PRICING ANALYSIS, BY REGION 52
5.3.2 PRICING ANALYSIS, BY PRODUCT 53
5.4 VALUE CHAIN ANALYSIS 53
5.5 SUPPLY CHAIN ANALYSIS 54
5.6 ECOSYSTEM ANALYSIS 55
5.6.1 FUSION BIOPSY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 56
5.7 PORTER’S FIVE FORCES ANALYSIS 57
5.7.1 THREAT OF NEW ENTRANTS 58
5.7.2 THREAT OF SUBSTITUTES 58
5.7.3 BARGAINING POWER OF BUYERS 58
5.7.4 BARGAINING POWER OF SUPPLIERS 59
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 59
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 59
5.8.2 BUYING CRITERIA 60
5.9 REGULATORY LANDSCAPE 61
5.9.1 NORTH AMERICA 61
5.9.1.1 US 61
5.9.1.2 Canada 62
5.9.2 EUROPE 62
?
5.9.3 ASIA PACIFIC 63
5.9.3.1 Japan 63
5.9.3.2 China 64
5.9.3.3 India 65
5.9.4 LATIN AMERICA 66
5.9.4.1 BRAZIL 66
5.9.4.2 MEXICO 66
5.9.5 MIDDLE EAST 66
5.9.6 AFRICA 67
5.9.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 67
5.10 TRADE ANALYSIS 69
5.10.1 TRADE ANALYSIS FOR FUSION BIOPSY MARKET 69
5.11 PATENT ANALYSIS 70
5.12 KEY CONFERENCES AND EVENTS IN 2024–2026 71
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 72
5.14 TECHNOLOGY ANALYSIS 73
5.14.1 KEY TECHNOLOGIES 73
5.14.1.1 MRI-ultrasound fusion imaging 73
5.14.2 COMPLEMENTARY TECHNOLOGIES 73
5.14.2.1 Liquid biopsy 73
5.14.2.1.1 Digital droplet PCR 73
5.14.2.1.2 Tagged-amplicon deep sequencing 74
5.15 INVESTMENT & FUNDING SCENARIO 74
5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE ON FUSION BIOPSY MARKET 74
6 FUSION BIOPSY MARKET, BY ROUTE TYPE 75
6.1 INTRODUCTION 76
6.2 TRANSRECTAL 76
6.2.1 HEIGHTENED POTENTIAL FOR SERIOUS INFECTIONS TO
HINDER MARKET GROWTH 76
6.3 TRANSPERINEAL 78
6.3.1 IMPROVED CANCER DETECTION THROUGH COMBINATION OF MRI AND ULTRASOUND TO FUEL MARKET GROWTH 78
6.4 OTHER ROUTE TYPES 80
7 FUSION BIOPSY MARKET, BY APPLICATION 83
7.1 INTRODUCTION 84
7.2 PROSTATE CANCER 84
7.2.1 PRECISE AND RELIABLE RESULTS OF PROSTATE FUSION BIOPSY TO ACCELERATE MARKET GROWTH 84
7.3 OTHER APPLICATIONS 87
?
8 FUSION BIOPSY MARKET, BY PRODUCT 89
8.1 INTRODUCTION 90
8.2 EQUIPMENT 90
8.2.1 SUBSTANTIAL INITIAL INVESTMENTS TO ENSURE MARKET GROWTH 90
8.3 CONSUMABLES 93
8.3.1 INCREASING APPLICATION OF INNOVATIVE TECHNOLOGIES AND METHODOLOGIES TO PROPEL MARKET GROWTH 93
9 FUSION BIOPSY MARKET, BY END USER 96
9.1 INTRODUCTION 97
9.2 HOSPITALS 97
9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO
PROMOTE MARKET GROWTH 97
9.3 OTHER END USERS 99
10 FUSION BIOPSY MARKET, BY REGION 102
10.1 INTRODUCTION 103
10.2 NORTH AMERICA 103
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 104
10.2.2 US 107
10.2.2.1 Funding for cancer research and availability of technologically advanced products to propel market growth 107
10.2.3 CANADA 109
10.2.3.1 Surging need for advanced diagnostic solutions to drive market 109
10.3 EUROPE 111
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 112
10.3.2 GERMANY 114
10.3.2.1 Rising healthcare expenditure and increasing incidence of cancer to bolster market growth 114
10.3.3 UK 116
10.3.3.1 Enhanced clinical infrastructure to accelerate fusion biopsy adoption 116
10.3.4 FRANCE 118
10.3.4.1 Effective reimbursement policies and government support for surgical product manufacturers to augment market 118
10.3.5 ITALY 120
10.3.5.1 Rising healthcare demands of geriatric population to
support market growth 120
10.3.6 SPAIN 122
10.3.6.1 Improved healthcare infrastructure and rising geriatric demographics to boost market 122
10.3.7 REST OF EUROPE 124
?
10.4 ASIA PACIFIC 127
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 127
10.4.2 CHINA 130
10.4.2.1 Increasing disposable income of middle-class population and rising diagnostic procedures to boost market 130
10.4.3 JAPAN 132
10.4.3.1 Robust healthcare system and surging need for precise early cancer detection to support market growth 132
10.4.4 INDIA 134
10.4.4.1 Large patient population and increasing healthcare
investments to drive market 134
10.4.5 REST OF ASIA PACIFIC 136
10.5 LATIN AMERICA 139
10.5.1 LOW FOCUS ON INFRASTRUCTURAL IMPROVEMENT AND POOR DISTRIBUTION OF RESOURCES LIKELY TO HINDER MARKET GROWTH 139
10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA & CARIBBEAN 141
10.6 MIDDLE EAST & AFRICA 143
10.6.1 EXPANDING ACCESS TO HEALTHCARE AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET 143
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 144
10.7 GCC COUNTRIES 146
10.7.1 ADVANCEMENTS AND INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO PROPEL MARKET 146
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 147
11 COMPETITIVE LANDSCAPE 150
11.1 OVERVIEW 150
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 150
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN
FUSION BIOPSY MARKET 150
11.3 REVENUE SHARE ANALYSIS, 2021–2023 151
11.4 MARKET SHARE ANALYSIS, 2023 152
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 154
11.5.1 STARS 154
11.5.2 EMERGING LEADERS 154
11.5.3 PERVASIVE PLAYERS 154
11.5.4 PARTICIPANTS 154
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 156
11.5.5.1 Company footprint 156
11.5.5.2 Region footprint 157
11.5.5.3 Route type footprint 158
11.5.5.4 Product footprint 158
11.5.5.5 Application footprint 159
11.5.5.6 End user footprint 159
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 160
11.6.1 PROGRESSIVE COMPANIES 160
11.6.2 STARTING BLOCKS 160
11.6.3 RESPONSIVE COMPANIES 160
11.6.4 DYNAMIC COMPANIES 160
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 162
11.7 COMPANY VALUATION & FINANCIAL METRICS, 2024 163
11.8 BRAND/PRODUCT COMPARISON 164
11.9 COMPETITIVE SCENARIO 165
11.9.1 PRODUCT LAUNCHES & APPROVALS 165
11.9.2 DEALS 165
12 COMPANY PROFILES 166
12.1 KEY PLAYERS 166
12.1.1 KONINKLIJKE PHILIPS N.V. 166
12.1.1.1 Business overview 166
12.1.1.2 Products offered 167
12.1.1.3 MnM view 168
12.1.1.3.1 Key strengths 168
12.1.1.3.2 Strategic choices 168
12.1.1.3.3 Weaknesses & competitive threats 168
12.1.2 GE HEALTHCARE 169
12.1.2.1 Business overview 169
12.1.2.2 Products offered 170
12.1.2.3 MnM view 171
12.1.2.3.1 Right to win 171
12.1.2.3.2 Strategic choices 171
12.1.2.3.3 Weaknesses & competitive threats 171
12.1.3 KOELIS 172
12.1.3.1 Business overview 172
12.1.3.2 Products offered 172
12.1.3.3 Recent developments 173
12.1.3.3.1 Deals 173
12.1.3.4 MnM view 173
12.1.3.4.1 Right to win 173
12.1.3.4.2 Strategic choices 173
12.1.3.4.3 Weaknesses & competitive threats 173
12.1.4 FUJIFILM HOLDINGS CORPORATION 174
12.1.4.1 Business overview 174
12.1.4.2 Products offered 175
12.1.4.3 Recent developments 176
12.1.4.3.1 Product launches & approvals 176
12.1.5 CANON INC. 177
12.1.5.1 Business overview 177
12.1.5.2 Products offered 178
12.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 179
12.1.6.1 Business overview 179
12.1.6.2 Products offered 180
12.1.7 ESAOTE SPA 181
12.1.7.1 Business overview 181
12.1.7.2 Products offered 181
12.1.8 EIGEN HEALTH 182
12.1.8.1 Business overview 182
12.1.8.2 Products offered 182
12.2 OTHER PLAYERS 184
12.2.1 FOCAL HEALTHCARE 184
12.2.2 MTT GMBH 185
12.2.3 MEDCOM 186
12.2.4 UC-CARE MEDICAL SYSTEMS 187
12.2.5 BIOBOT SURGICAL 187
13 APPENDIX 188
13.1 DISCUSSION GUIDE 188
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 192
13.3 CUSTOMIZATION OPTIONS 194
13.4 RELATED REPORTS 195
13.5 AUTHOR DETAILS 196



List of Figures

FIGURE 1 FUSION BIOPSY MARKET SEGMENTATION & REGIONAL SCOPE 21
FIGURE 2 FUSION BIOPSY MARKET: RESEARCH DESIGN 24
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 28
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE DESIGNATION, AND REGION 29
FIGURE 5 FUSION BIOPSY MARKET: REVENUE SHARE ANALYSIS 30
FIGURE 6 APPROACH BASED ON PATIENT POPULATION 31
FIGURE 7 APPROACH BASED ON NUMBER OF HOSPITALS 33
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 34
FIGURE 9 FUSION BIOPSY MARKET: TOP-DOWN APPROACH 35
FIGURE 10 DATA TRIANGULATION METHODOLOGY 36
FIGURE 11 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2024 VS. 2029 (USD MILLION) 39
FIGURE 12 FUSION BIOPSY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 40
FIGURE 13 FUSION BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 40
FIGURE 14 FUSION BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 41
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF FUSION BIOPSY MARKET 42
FIGURE 16 INCREASING PREVALENCE OF PROSTATE CANCER TO DRIVE MARKET GROWTH 43
FIGURE 17 PROSTATE CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF
NORTH AMERICAN MARKET IN 2023 44
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 44
FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 45
FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH
DURING FORECAST PERIOD 45
FIGURE 21 FUSION BIOPSY MARKET: DRIVERS, RESTRAINTS OPPORTUNITIES, AND CHALLENGES 46
FIGURE 22 VALUE CHAIN ANALYSIS OF FUSION BIOPSY MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 54
FIGURE 23 FUSION BIOPSY MARKET: SUPPLY CHAIN ANALYSIS 55
FIGURE 24 FUSION BIOPSY MARKET: ECOSYSTEM ANALYSIS 56
FIGURE 25 KEY PLAYERS IN FUSION BIOPSY MARKET ECOSYSTEM 56
FIGURE 26 FUSION BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 58
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
FUSION BIOPSY END USERS 59
FIGURE 28 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS 60
FIGURE 29 PATENT ANALYSIS FOR FUSION BIOPSY MARKET, JANUARY 2014–OCTOBER 2024 70
FIGURE 30 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN
FUSION BIOPSY MARKET 72
FIGURE 31 FUSION BIOPSY MARKET: INVESTMENT & FUNDING SCENARIO 74
FIGURE 32 NORTH AMERICA: FUSION BIOPSY MARKET SNAPSHOT 105
FIGURE 33 ASIA PACIFIC: FUSION BIOPSY MARKET SNAPSHOT 128
FIGURE 34 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN FUSION
BIOPSY MARKET, 2021–2023 152
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN FUSION BIOPSY MARKET (2023) 152
FIGURE 36 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 155
FIGURE 37 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 161
FIGURE 38 EV/EBITDA OF KEY VENDORS, 2024 163
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK
BETA OF KEY VENDORS 163
FIGURE 40 FUSION BIOPSY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 164
FIGURE 41 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 167
FIGURE 42 GE HEALTHCARE: COMPANY SNAPSHOT (2023) 170
FIGURE 43 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024) 175
FIGURE 44 CANON INC.: COMPANY SNAPSHOT (2023) 178
FIGURE 45 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:
COMPANY SNAPSHOT (2022) 180

List of Tables

TABLE 1 RISK ASSESSMENT 38
TABLE 2 PROSTATE CANCER INCIDENCE, BY REGION, 2022 47
TABLE 3 AVERAGE SELLING PRICE TREND OF FUSION BIOPSY PRODUCTS BY REGION, 2021–2023 52
TABLE 4 PRICING ANALYSIS OF FUSION BIOPSY PRODUCTS, 2021–2023 53
TABLE 5 FUSION BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 57
TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
FUSION BIOPSY END USERS (%) 60
TABLE 7 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS 60
TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION 61
TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 62
TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 62
TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 63
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES 64
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 67
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 67
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 68
TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 68
TABLE 17 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 18 IMPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY 2019–2023 (USD MILLION) 69
TABLE 19 EXPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY 2019–2023 (USD MILLION) 69
TABLE 20 FUSION BIOPSY MARKET: KEY CONFERENCES AND EVENTS IN 2024–2026 71
TABLE 21 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 76
TABLE 22 FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY REGION 2022–2029 (USD MILLION) 77
TABLE 23 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES BY COUNTRY, 2022–2029 (USD MILLION) 77
TABLE 24 EUROPE: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES BY COUNTRY, 2022–2029 (USD MILLION) 78
TABLE 25 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES BY COUNTRY, 2022–2029 (USD MILLION) 78
TABLE 26 FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY REGION 2022–2029 (USD MILLION) 79
TABLE 27 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 79
TABLE 28 EUROPE: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES BY COUNTRY, 2022–2029 (USD MILLION) 80
TABLE 29 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES BY COUNTRY, 2022–2029 (USD MILLION) 80
TABLE 30 FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY REGION 2022–2029 (USD MILLION) 81
TABLE 31 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES BY COUNTRY, 2022–2029 (USD MILLION) 81
TABLE 32 EUROPE: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 82
TABLE 33 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 82
TABLE 34 FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 84
TABLE 35 PROSTATE CANCER INCIDENCE, BY REGION, 2022 85
TABLE 36 FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY REGION 2022–2029 (USD MILLION) 85
TABLE 37 NORTH AMERICA: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 86
TABLE 38 EUROPE: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY 2022–2029 (USD MILLION) 86
TABLE 39 ASIA PACIFIC: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 86
TABLE 40 FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY REGION 2022–2029 (USD MILLION) 87
TABLE 41 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 88
TABLE 42 EUROPE: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 88
TABLE 43 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 88
TABLE 44 FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 90
TABLE 45 KEY PRODUCTS IN FUSION BIOPSY EQUIPMENT MARKET 91
TABLE 46 FUSION BIOPSY MARKET FOR EQUIPMENT, BY REGION 2022–2029 (USD MILLION) 91
TABLE 47 NORTH AMERICA: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY 2022–2029 (USD MILLION) 92
TABLE 48 EUROPE: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY 2022–2029 (USD MILLION) 92
TABLE 49 ASIA PACIFIC: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY 2022–2029 (USD MILLION) 92
TABLE 50 KEY PRODUCTS IN FUSION BIOPSY CONSUMABLES MARKET 93
TABLE 51 FUSION BIOPSY MARKET FOR CONSUMABLES, BY REGION 2022–2029 (USD MILLION) 94
TABLE 52 NORTH AMERICA: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 53 EUROPE: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY 2022–2029 (USD MILLION) 95
TABLE 54 ASIA PACIFIC: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY 2022–2029 (USD MILLION) 95
TABLE 55 FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 97
TABLE 56 FUSION BIOPSY MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 98
TABLE 57 NORTH AMERICA: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY 2022–2029 (USD MILLION) 98
TABLE 58 EUROPE: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY 2022–2029 (USD MILLION) 99
TABLE 59 ASIA PACIFIC: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY 2022–2029 (USD MILLION) 99
TABLE 60 FUSION BIOPSY MARKET FOR OTHER END USERS, BY REGION 2022–2029 (USD MILLION) 100
TABLE 61 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 62 EUROPE: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY 2022–2029 (USD MILLION) 101
TABLE 63 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 64 FUSION BIOPSY MARKET, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 65 NORTH AMERICA: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022 104
TABLE 66 NORTH AMERICA: MACROECONOMIC OUTLOOK 104
TABLE 67 NORTH AMERICA: FUSION BIOPSY MARKET, BY COUNTRY 2022–2029 (USD MILLION) 105
TABLE 68 NORTH AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE 2022–2029 (USD MILLION) 106
TABLE 69 NORTH AMERICA: FUSION BIOPSY MARKET, BY PRODUCT 2022–2029 (USD MILLION) 106
TABLE 70 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION 2022–2029 (USD MILLION) 106
TABLE 71 NORTH AMERICA: FUSION BIOPSY MARKET, BY END USER 2022–2029 (USD MILLION) 107
TABLE 72 US: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022–2029 (NUMBER PER 1,000 PERSONS) 108
TABLE 73 US: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 108
TABLE 74 US: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 108
TABLE 75 US: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 109
TABLE 76 US: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 109
TABLE 77 CANADA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 110
TABLE 78 CANADA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 110
TABLE 79 CANADA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 110
TABLE 80 CANADA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 111
TABLE 81 EUROPE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE BY CANCER TYPE, 2022 111
TABLE 82 EUROPE: MACROECONOMIC OUTLOOK 112
TABLE 83 EUROPE: FUSION BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 84 EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 113
TABLE 85 EUROPE: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 113
TABLE 86 EUROPE: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 113
TABLE 87 EUROPE: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 114
TABLE 88 GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE BY CANCER TYPE, 2022 114
TABLE 89 GERMANY: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022–2029 (NUMBER PER 1,000 PERSONS) 115
TABLE 90 GERMANY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 115
TABLE 91 GERMANY: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 115
TABLE 92 GERMANY: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 116
TABLE 93 GERMANY: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 116
TABLE 94 UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 117
TABLE 95 UK: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 117
TABLE 96 UK: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 117
TABLE 97 UK: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 118
TABLE 98 UK: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 118
TABLE 99 FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE BY CANCER TYPE, 2022 119
TABLE 100 FRANCE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 119
TABLE 101 FRANCE: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 119
TABLE 102 FRANCE: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 120
TABLE 103 FRANCE: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 120
TABLE 104 ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE BY CANCER TYPE, 2022 121
TABLE 105 ITALY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 121
TABLE 106 ITALY: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 121
TABLE 107 ITALY: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 122
TABLE 108 ITALY: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 122
TABLE 109 SPAIN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE BY CANCER TYPE, 2022 123
TABLE 110 SPAIN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 123
TABLE 111 SPAIN: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 123
TABLE 112 SPAIN: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 124
TABLE 113 SPAIN: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 124
TABLE 114 REST OF EUROPE: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022 125
TABLE 115 REST OF EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE 2022–2029 (USD MILLION) 125
TABLE 116 REST OF EUROPE: FUSION BIOPSY MARKET, BY PRODUCT 2022–2029 (USD MILLION) 126
TABLE 117 REST OF EUROPE: FUSION BIOPSY MARKET, BY APPLICATION 2022–2029 (USD MILLION) 126
TABLE 118 REST OF EUROPE: FUSION BIOPSY MARKET, BY END USER 2022–2029 (USD MILLION) 126
TABLE 119 ASIA PACIFIC: MACROECONOMIC OUTLOOK 127
TABLE 120 ASIA PACIFIC: FUSION BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 121 ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE 2022–2029 (USD MILLION) 129
TABLE 122 ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 129
TABLE 123 ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION 2022–2029 (USD MILLION) 130
TABLE 124 ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 130
TABLE 125 CHINA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 131
TABLE 126 CHINA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 131
TABLE 127 CHINA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 131
TABLE 128 CHINA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 132
TABLE 129 CHINA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 132
TABLE 130 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 133
TABLE 131 JAPAN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 133
TABLE 132 JAPAN: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 133
TABLE 133 JAPAN: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 134
TABLE 134 JAPAN: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 134
TABLE 135 INDIA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 135
TABLE 136 INDIA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022–2029 (USD MILLION) 135
TABLE 137 INDIA: FUSION BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 136
TABLE 138 INDIA: FUSION BIOPSY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 136
TABLE 139 INDIA: FUSION BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 136
TABLE 140 PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2030 137
TABLE 141 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE 2022–2029 (USD MILLION) 138
TABLE 142 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT 2022–2029 (USD MILLION) 138
TABLE 143 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION 2022–2029 (USD MILLION) 138
TABLE 144 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER 2022–2029 (USD MILLION) 139
TABLE 145 LATIN AMERICA: PROSTATE CANCER INCIDENCE, 2022 140
TABLE 146 LATIN AMERICA & CARIBBEAN: MACROECONOMIC OUTLOOK 141
TABLE 147 LATIN AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE 2022–2029 (USD MILLION) 141
TABLE 148 LATIN AMERICA: FUSION BIOPSY MARKET, BY PRODUCT 2022–2029 (USD MILLION) 142
TABLE 149 LATIN AMERICA: FUSION BIOPSY MARKET, BY APPLICATION 2022–2029 (USD MILLION) 142
TABLE 150 LATIN AMERICA: FUSION BIOPSY MARKET, BY END USER 2022–2029 (USD MILLION) 142
TABLE 151 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE BY CANCER TYPE, 2022 144
TABLE 152 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 144
TABLE 153 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY ROUTE TYPE 2022–2029 (USD MILLION) 145
TABLE 154 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY PRODUCT 2022–2029 (USD MILLION) 145
TABLE 155 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY APPLICATION 2022–2029 (USD MILLION) 145
TABLE 156 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY END USER 2022–2029 (USD MILLION) 146
TABLE 157 GCC COUNTRIES: MACROECONOMIC OUTLOOK 147
TABLE 158 GCC COUNTRIES: FUSION BIOPSY MARKET, BY ROUTE TYPE 2022–2029 (USD MILLION) 148
TABLE 159 GCC COUNTRIES: FUSION BIOPSY MARKET, BY PRODUCT 2022–2029 (USD MILLION) 148
TABLE 160 GCC COUNTRIES: FUSION BIOPSY MARKET, BY APPLICATION 2022–2029 (USD MILLION) 148
TABLE 161 GCC COUNTRIES: FUSION BIOPSY MARKET, BY END USER 2022–2029 (USD MILLION) 149
TABLE 162 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS 150
TABLE 163 FUSION BIOPSY MARKET: DEGREE OF COMPETITION 153
TABLE 164 FUSION BIOPSY MARKET: COMPANY FOOTPRINT 156
TABLE 165 FUSION BIOPSY MARKET: REGION FOOTPRINT 157
TABLE 166 FUSION BIOPSY MARKET: ROUTE TYPE FOOTPRINT 158
TABLE 167 FUSION BIOPSY MARKET: PRODUCT FOOTPRINT 158
TABLE 168 FUSION BIOPSY MARKET: APPLICATION FOOTPRINT 159
TABLE 169 FUSION BIOPSY MARKET: END USER FOOTPRINT 159
TABLE 170 FUSION BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 162
TABLE 171 FUSION BIOPSY MARKET: COMPETITIVE BENCHMARKING OF
KEY EMERGING PLAYERS/STARTUPS 162
TABLE 172 FUSION BIOPSY MARKET: PRODUCT LAUNCHES & APPROVALS JANUARY 2021–MARCH 2024 165
TABLE 173 FUSION BIOPSY MARKET: DEALS, JANUARY 2021–MARCH 2024 165
TABLE 174 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW 166
TABLE 175 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 167
TABLE 176 GE HEALTHCARE: BUSINESS OVERVIEW 169
TABLE 177 GE HEALTHCARE: PRODUCTS OFFERED 170
TABLE 178 KOELIS: BUSINESS OVERVIEW 172
TABLE 179 KOELIS: PRODUCT OFFERED 172
TABLE 180 KOELIS: DEALS, JANUARY 2021–MARCH 2024 173
TABLE 181 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 174
TABLE 182 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED 175
TABLE 183 FUJIFILM HOLDINGS CORPORATION: PRODUCT LAUNCHES & APPROVALS JANUARY 2021–MARCH 2024 176
TABLE 184 CANON INC.: BUSINESS OVERVIEW 177
TABLE 185 CANON INC.: PRODUCTS OFFERED 178
TABLE 186 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: BUSINESS OVERVIEW 179
TABLE 187 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 180
TABLE 188 ESAOTE SPA: BUSINESS OVERVIEW 181
TABLE 189 ESAOTE SPA: PRODUCTS OFFERED 181
TABLE 190 EIGEN HEALTH: COMPANY OVERVIEW 182
TABLE 191 EIGEN HEALTH: PRODUCTS OFFERED 182